Insights

Professional
Practice
Industry
Region
Trending Topics
Location
Type

Sort by:

Firm News 1 result

Firm News | 2 min read | 05.30.24

Crowell & Moring Honors Recipients of 25th Annual George Bailey Public Service Awards

Washington, D.C. – May 30, 2024: Crowell & Moring hosted its 25thannual George Bailey Public Service Awards ceremony. Named after the hero of the classic movie, “It’s a Wonderful Life,” these awards recognize the firm’s lawyers and staff who have made a substantial impact on the lives of others through their pro bono work.
...

Client Alerts 6 results

Client Alert | 12 min read | 03.19.25

Right To Repair – A Growing Trend for States Creating Compliance Challenges for Manufacturers

In 2023 and 2024, several U.S. states enacted extensive “Right to Repair” laws, reflecting a growing legislative focus on ensuring consumers have access to the parts and resources needed to repair their own products without relying on the product’s original manufacturer. Most recently, California, Colorado, Minnesota, New York, Massachusetts, and Oregon implemented comprehensive regulations aimed at providing consumers direct access to tools, parts, and information for the repair of various electronic devices and equipment, including digital products and agricultural machinery. As the “Right to Repair” movement continues to gain significant traction across the United States, it is critical that manufacturers understand these laws and how these laws will impact their individual businesses.
...

Client Alert | 3 min read | 12.24.24

Only Drugs Allowed: Federal Circuit Affirms Order To Delist Device Patents From the Orange Book

On December 20, 2024, the Federal Circuit affirmed a district court’s holding that five device patents had been improperly listed in the Orange Book by Teva Pharmaceuticals, Inc. as claiming a drug, and ordering that they be delisted.
...

Client Alert | 2 min read | 06.27.24

The FTC Strikes Out: Drug Manufacturers Refuse to Play Ball and Delist Orange Book Patents in Response to FTC Warning Letters

As reported in earlier Client Alerts, on November 7, 2023, the Federal Trade Commission challenged 100 patents as improperly listed in the Food and Drug Administration’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication, commonly known as the Orange Book. The FTC sent warning letters to ten drug and medical device manufacturers identifying patents for inhalers, autoinjectors and anti-inflammatory multi-dose bottles that the FTC believes are improperly listed. In response, some manufacturers withdrew their patents, and others agreed to cap certain out-of-pocket costs for their drugs, resulting in a “victory lap” of media activity from the FTC in April.
...

Blog Posts 14 results

Blog Post | 03.19.25

Taking Aim at Humphrey’s Executor: Trump Fires the FTC’s Democratic Commissioners

Crowell & Moring’s Retail & Consumer Products Law Observer

Blog Post | 03.17.25

FTC Updates (February 3- 21, 2025)

Crowell & Moring’s Retail & Consumer Products Law Observer

Blog Post | 12.03.24

FTC Updates (November 18-29, 2024)

Crowell & Moring’s Retail & Consumer Products Law Observer